경구 항생제 시장 보고서 : 클래스별, 용도별, 약제 원료별, 항균 스펙트럼별, 약제 유형별, 지역별(2026-2034년)

The global oral antibiotics market size reached USD 21,749.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 28,759.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.06% during 2026-2034. The increasing prevalence of infectious diseases, expanding geriatric population, escalating demand for effective treatments against drug-resistant bacteria, and the growing trend of personalized medicine and genomics represent some of the key factors driving the market.

Oral antibiotics are pharmaceutical agents primarily prescribed to inhibit bacterial growth or eliminate bacteria from the body. They are usually taken by mouth and are utilized across a wide range of medical applications. The types of infections treated by oral antibiotics vary and include common ailments such as skin, ear, throat, and urinary tract infections and more complex conditions like certain types of pneumonia. These antibiotics are categorized into different classes, each with a distinct mechanism of action. Some commonly prescribed classes include penicillins, fluoroquinolones, tetracyclines, and macrolides. Each class targets different types of bacteria and is more effective for specific bacterial infections. For instance, penicillins are widely used for streptococcal infections, while fluoroquinolones may be chosen to combat certain gram-negative bacteria. As a result, oral antibiotics are a key element of modern healthcare and are widely prescribed by healthcare professionals to enable the successful treatment of numerous bacterial infections.

ORAL ANTIBIOTICS MARKET TRENDS:

The increasing prevalence of infectious diseases and the rising public awareness about the available treatment options for these conditions represent the primary factors supporting market growth. Moreover, the expanding geriatric population that is more susceptible to developing such infections is another major factor fueling the market growth. In addition, there has been a rise in antibiotic stewardship programs aimed at encouraging the widespread use of antibiotics, slowing down the emergence of antibiotic resistance, and ensuring the prolonged effectiveness of these drugs. Along with this, the growing issue of antibiotic resistance has compelled researchers and pharmaceutical companies to modify existing classes and develop new antibiotics capable of treating multi-drug resistant bacteria, thereby accelerating the product adoption rate. Furthermore, the leading pharmaceutical companies and research institutes are leveraging artificial intelligence (AI) and machine learning (ML) in the drug discovery process to predict bacterial resistance patterns, understand drug-bacteria interactions, and expedite the discovery of novel antibiotics. In line with this, the emergence of personalized medicine and genomics, which involves tailoring antibiotic treatment to individual patients by considering factors such as their genetic makeup to enhance treatment effectiveness and minimize side effects, has catalyzed market growth. Other factors, including escalating demand for effective treatments against drug-resistant bacteria, improving healthcare infrastructure, the continual launch of novel oral antibiotics, and heavy investments in research and development (R&D) activities, are also anticipated to propel the market growth in the coming years.

KEY MARKET SEGMENTATION:

Class Insights:

• Beta Lactam and Beta Lactamase Inhibitors
  • Penicillin
  • Cephalosporin
  • Others
• Quinolone
• Macrolide

Application Insights:

• Community-acquired Respiratory Tract Infections (CARTIs)
  • Upper Respiratory Tract Infections (URTI)
  • Lower Respiratory Tract Infections (LRTIs)
• Urinary Tract Infections (UTIs)
• Dental
  • Combination
  • Monotherapies

Drug Origin Insights:

• Natural
• Semisynthetic
• Synthetic

Spectrum of Activity Insights:

• Broad-spectrum Antibiotic
• Narrow Spectrum Antibiotic

Drug Type Insights:

• Branded
• Generics

Regional Insights:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia-Pacific was the largest market for oral antibiotics. Some of the factors driving the Asia-Pacific oral antibiotics market included its aging population, growing burden of infectious diseases, high healthcare expenditure, the presence of various key players, etc.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global oral antibiotics market. Detailed profiles of all major companies have been provided. Some of the companies covered include Bayer AG, Cipla Inc., Gilead Sciences Inc., Janssen Inc. (Johnson & Johnson Services, Inc.), Pfizer Inc., Roche Holding AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global oral antibiotics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global oral antibiotics market?
• What is the impact of each driver, restraint, and opportunity on the global oral antibiotics market?
• What are the key regional markets?
• Which countries represent the most attractive oral antibiotics market?
• What is the breakup of the market based on the class?
• Which is the most attractive class in the oral antibiotics market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the oral antibiotics market?
• What is the breakup of the market based on the drug origin?
• Which is the most attractive drug origin in the oral antibiotics market?
• What is the breakup of the market based on the spectrum of activity?
• Which is the most attractive spectrum of activity in the oral antibiotics market?
• What is the breakup of the market based on the drug type?
• Which is the most attractive drug type in the oral antibiotics market?
• What is the competitive structure of the global oral antibiotics market?
• Who are the key players/companies in the global oral antibiotics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Oral Antibiotics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Class

• 6.1 Beta Lactam and Beta Lactamase Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Penicillin
    • 6.1.2.2 Cephalosporin
    • 6.1.2.3 Others
  • 6.1.3 Market Forecast
• 6.2 Quinolone
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Macrolide
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Application

• 7.1 Community-acquired Respiratory Tract Infections (CARTIs)
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Upper Respiratory Tract Infections (URTI)
    • 7.1.2.2 Lower Respiratory Tract Infections (LRTIs)
  • 7.1.3 Market Forecast
• 7.2 Urinary Tract Infections (UTIs)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Dental
  • 7.3.1 Market Trends
  • 7.3.2 Key Segments
    • 7.3.2.1 Combination
    • 7.3.2.2 Monotherapies
  • 7.3.3 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Drug Origin

• 8.1 Natural
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Semisynthetic
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Synthetic
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Spectrum of Activity

• 9.1 Broad-spectrum Antibiotic
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Narrow Spectrum Antibiotic
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Drug Type

• 10.1 Branded
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Generics
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

• 12.1 Overview
• 12.2 Drivers
• 12.3 Restraints
• 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Bayer AG
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Cipla Inc
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 Gilead Sciences Inc
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
    • 16.3.3.4 SWOT Analysis
  • 16.3.4 Janssen Inc. (Johnson & Johnson Services, Inc)
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
  • 16.3.5 Pfizer Inc.
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 Roche Holding AG
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
  • 16.3.7 Sun Pharmaceutical Industries Ltd
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Teva Pharmaceutical Industries Ltd.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis